Blar i forfatter "Brustugun, Odd Terje"

Viser treff 1-12 av 12

    • Clinical significance of disseminated tumour cells in non-small cell lung cancer 

      Rud, Ane Kristine Kongsgaard; Borgen, Elin; Mælandsmo, Gunhild; Flatmark, Kjersti; Le, Hang Ngoc Thi; Josefsen, Dag; Solvoll, Ingjerd; Schirmer, Cecilie; Helland, Åslaug; Jørgensen, Lars Hilmar; Brustugun, Odd Terje; Fodstad, Øystein; Boye, Kjetil (Journal article; Tidsskriftartikkel; Peer reviewed, 2013-08-13)
      Background: Early-stage non-small cell lung cancer (NSCLC) patients have a high risk of disease relapse despite curatively intended surgical resection, and the detection of tumour cells in the bone marrow could be one method of determining the presence of the disseminated disease in its early stages.<p> <p>Methods: Bone marrow aspirates were collected from 296 patients at the time of surgery, and ...

    • Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer 

      Halvorsen, Tarje Onsøien; Sundstrøm, Stein Harald; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Kaasa, Stein; Grønberg, Bjørn Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-08-23)
      <b>Background:</b> Many patients with limited disease small cell lung cancer (LD SCLC) suffer from comorbidity. Not all patients with comorbidity are offered standard treatment, though there is little evidence for such a policy. The aim of this study was to investigate whether patients with comorbidity had inferior outcomes in a LD SCLC cohort. <br><b>Material and methods:</b> We analyzed patients ...

    • Concordance between clinical and pathology TNM-staging in lung cancer 

      Solberg, Steinar; Nilssen, Yngvar; Brustugun, Odd Terje; Haram, Per Magnus; Helland, Åslaug; Møller, Bjørn; Strand, Trond-Eirik; Wahl, Sissel Gyrid Freim; Fjellbirkeland, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-07-25)
      Objectives: A prerequisite for utilizing the tumour, lymph-nodes, and metastases (TNM) for the staging of lung cancer patients is a high quality of the reported data on which the staging is based. The aim of this study was to investigate the concordance between the clinical, cTNM and the pathology, pTNM staging for lung cancer, version 8 as reported to the Cancer Registry of Norway (CRN).<p> < ...

    • Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer 

      Rud, Ane Kristine Kongsgaard; Pedersen, Kjetil Boye; Fodstad, Øystein; Juell, Siri; Jørgensen, Lars Hilmar; Solberg, Steinar; Helland, Åslaug; Brustugun, Odd Terje; Mælandsmo, Gunhild (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-06-17)
      Background: The regional lymph node involvement is a major prognostic factor in patients with non-small cell lung cancer (NSCLC) undergoing surgical resection. Disease relapse is common, suggesting that early disseminated disease is already present in the regional lymph nodes at the time of surgery, and that the current nodal staging classification might be suboptimal. Early detection of disseminated ...

    • Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer 

      Rud, Ane Kristine Kongsgaard; Lund-Iversen, Marius; Berge, Gisle; Brustugun, Odd Terje; Solberg, Steinar; Mælandsmo, Gunhild; Pedersen, Kjetil Boye (Journal article; Tidsskriftartikkel; Peer reviewed, 2012)
      The metastasis-promoting protein S100A4 induces expression of ephrin-A1 and osteopontin in osteosarcoma cell lines. The aim of this study was to investigate S100A4-mediated stimulation of ephrin-A1 and osteopontin in non-small cell lung cancer (NSCLC) cell lines, and to characterize the expression of these biomarkers in primary tumor tissue from NSCLC patients. Four NSCLC cell lines were treated ...

    • High number of kinome-mutations in non-small cell lung cancers associated with reduced immune response and poor relapse-free survival 

      Helland, Åslaug; Brustugun, Odd Terje; Nakken, Sigve; Halvorsen, Ann Rita; Dønnem, Tom; Bremnes, Roy M.; Busund, Lill-Tove; Sun, Jinchang; Lorenz, Susanne; Solberg, Steinar; Jørgensen, Lars Hilmar; Vodak, Daniel; Myklebost, Ola; Hovig, Eivind; Meza, Leonardo Zepeda (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-04-07)
      Lung cancer is the leading cause of cancer related death, and the past years’ improved insight into underlying molecular events has significantly improved outcome for specific subsets of patients. In particular, several new therapies that target protein kinases have been implemented, and many more are becoming available. We have investigated lung cancer specimens for somatic mutations in a targeted ...

    • Mutasjonstesting ved ikke-småcellet lungekreft 

      Brustugun, Odd Terje; Helland, Åslaug; Fjellbirkeland, Lars; Kleinberg, Lilach; Ariansen, Sarah Louise; Jebsen, Peter Wilhelm; Scott, Helge; Dønnem, Tom; Bremnes, Roy M.; Berg, Thomas; Grønberg, Bjørn Henning; Dai, Hong Yan; Wahl, Sissel Gyrid Freim; Mangseth, Kjersti; Helgeland, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-04-30)
      Bakgrunn. Epidermal vekstfaktorreseptor (EGFR) tyrosinkinasehemmere (EGFR-TKI) er en relativt ny klasse legemidler til behandling av ikke-småcellet lungekreft. Den nasjonale faggruppen for lungekreft, Norsk Lunge Cancer Gruppe, anbefaler at pasienter med ikke-småcellet lungekreft testes for mutasjoner i EGFRgenet. Vi rapporterer her erfaringene som er gjort etter at slik testing ble innført i ...

    • Osteopontin is a prognostic biomarker in non-small cell lung cancer 

      Rud, Ane Kristine Kongsgaard; Pedersen, Kjetil Boye; Øijordsbakken, Miriam; Lund-Iversen, Marius; Halvorsen, Ann Rita; Solberg, Steinar; Berge, Gisle; Helland, Åslaug; Brustugun, Odd Terje; Mælandsmo, Gunhild (Journal article; Tidsskriftartikkel; Peer reviewed, 2013)
      Background: In a previously published report we characterized the expression of the metastasis-associated proteins S100A4, osteopontin (OPN) and ephrin-A1 in a prospectively collected panel of non-small cell lung cancer (NSCLC) tumors. The aim of the present follow-up study was to investigate the prognostic impact of these potential biomarkers in the same patient cohort. In addition, circulating ...

    • Protein kinase C isozymes associated with relapse free survival in non-small cell lung cancer patients 

      Halvorsen, Ann Rita; Haugen, Mads Haugland; Øjlert, Åsa Kristina; Lund-Iversen, Marius; Jørgensen, Lars Hilmar; Solberg, Steinar; Mælandsmo, Gunhild Mari; Brustugun, Odd Terje; Helland, Åslaug (Journal article; Tidsskriftartikkel, 2020-11-25)
      <i>Introduction</i>: Protein expression is deregulated in cancer, and the proteomic changes observed in lung cancer may be a consequence of mutations in essential genes. The purpose of this study was to identify protein expression associated with prognosis in lung cancers stratified by smoking status, molecular subtypes, and EGFR-, TP53-, and KRAS-mutations.<p> <p><i>Methods</i>: We performed ...

    • Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer 

      Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Tollåli, Terje; Hornslien, Kjersti; Aksnessæther, Bjørg Y.; Liaaen, Erik Dyb; Sundstrøm, Stein Harald (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-10-23)
      <br>BACKGROUND: <br> Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well documented, but not universally implemented - probably mainly due to inconvenience and concerns about toxicity. A schedule of three-week hypofractionated TRT is a commonly used alternative. This is the first randomized trial ...

    • Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement 

      Valan, Christine Damgaard; Slagsvold, Jens Erik; Halvorsen, Tarje Onsøien; Herje, Martin; Bremnes, Roy M.; Brunsvig, Paal Fr.; Brustugun, Odd Terje; Fløtten, Øystein; Levin, Nina; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-02)
      Background/Aim: <br>There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules of thoracic radiotherapy (TRT) in LD SCLC to investigate whether there were survival differences between N3 subcategories (n=144). Patients and <br>Methods: <br>Patients ...

    • Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer 

      Halvorsen, Tarje Onsøien; Herje, Martin; Levin, Nina; Bremnes, Roy M.; Brustugun, Odd Terje; Fløtten, Øystein; Kaasa, Stein; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-10-15)
      Objectives: <br> Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small-cell lung cancer (LD SCLC). TRT should start as early as possible, often meaning with the second course due to patient referral time and the fact that TRT planning takes time. Early assessment of response to the first course of chemotherapy may be a useful way to individualise treatment. ...